- Home
- CYCN vs IMCC Comparison
CYCN vs IMCC Comparison
Compare CYCN & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYCN | IMCC |
|---|---|---|
| Founded | 2018 | 1980 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 10.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CYCN | IMCC |
|---|---|---|
| Price | $1.51 | $1.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.4K | ★ 197.7K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,855,000.00 | ★ $37,606,703.00 |
| Revenue This Year | N/A | $47.12 |
| Revenue Next Year | N/A | $12.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1371.65 | 1.92 |
| 52 Week Low | $1.28 | $0.93 |
| 52 Week High | $6.25 | $7.12 |
Technical Indicators
Market Signals| Indicator | CYCN | IMCC |
|---|---|---|
| Relative Strength Index (RSI) | 41.63 | 59.41 |
| Support Level | $1.63 | $1.54 |
| Resistance Level | $1.77 | $1.84 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 20.51 | 69.33 |
Price Performance
Historical ComparisonAbout CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.